Drug intelligence / Profile preview

Asmanex

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Inhalation

Overview

Asmanex is an inhaled corticosteroid (ICS) containing the active ingredient mometasone furoate, primarily indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. It functions as a potent glucocorticoid receptor agonist, exerting local anti-inflammatory effects in the lungs to reduce airway hyperresponsiveness and prevent asthma exacerbations. Originally developed by Schering-Plough (later Merck & Co.), the product is currently part of the Organon portfolio following its spin-off in 2021. It is available in two main formulations: the Asmanex Twisthaler, a dry powder inhaler (DPI), and Asmanex HFA, a metered-dose inhaler (MDI).

Brand names: AsmanexAsmanex TwisthalerAsmanex HFA
Other names: mometasone furoate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Asmanex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asmanex.

Explore the full profile